Cypherpunk's Zcash-fuelled profit masks open question over Leap's colorectal cancer drug
A large non-cash gain lifted the former Leap Therapeutics to a $306M quarterly profit, while the fate of sirexatamab now hinges on finding outside backing.
16 Nov 2026 · Cypherpunk Technologies Inc. CYPH · Company news
Cypherpunk Technologies, the Nasdaq-listed company that was formerly Leap Therapeutics, posted third-quarter 2026 net income of $306M on 16 November. The company puts the result down to a sizeable non-cash derivative gain rather than to trading in its drug business.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
or
Company's press release (SEC filing): Cypherpunk Technologies Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
More EarningsAll →
Earnings
Prenetics widens H2 EBITDA loss guidance to $30-35M as IM8 spending rises
18 Nov 2026 · Prenetics Global Ltd PRE · Company news
Earnings
newcleo reports Q3 revenue of about €10M and €233.4M cash as PRECURSOR e-core completed
18 Nov 2026 · newcleo plc NWCL · Company news
Earnings
Iridex cuts 2026 revenue guidance to $46-48M after 19% third-quarter sales drop
17 Nov 2026 · Iridex Corp IRIX · Company news
Earnings
Interpace Biosciences Q3 revenue rises 18% to $10.4M on thyroid testing growth
17 Nov 2026 · Interpace Biosciences, Inc. IDXG · Company news
Earnings
Zentek reports C$15.2M six-month profit on impairment reversal; cash rises to C$13.6M
17 Nov 2026 · Zentek Ltd. ZTEKF · Company news
Earnings
Vivos Therapeutics regains Nasdaq equity compliance as Q3 revenue rises 24% sequentially
17 Nov 2026 · Vivos Therapeutics, Inc. VVOS · Company news